No description yet.
Haddonfield, NJBiotechFounded 2016
1 source · checked 2 times, last 13h ago
The filing describes an equity offering but does not identify a financing stage, valuation, announcement date, or named investors.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Form D (equity) | $3.7M | 2026-11-16 | not stated | 1 outlet. #128 in Trending |
1 source · checked 2 times, last 13h ago [ VERIFIED ] read against 1 source The filing describes an equity offering but does not identify a financing stage, valuation, announcement date, or named investors. [ BUILT WITH ]·[ SEARCH ]from a Form D filing·[ SCRAPE ]1 page read: sec.gov·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ AGENT ]company research by the Firecrawl agent | ||||
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series B | almost $4.5 million | undated | not stated | |
| Financing | $1.6 million | undated | not stated | |
| Series B | $12 million | 2019-09-17 | Kairos Ventures | |
Linnaeus Therapeutics develops small-molecule medicines that activate GPER to treat cancer, cardiometabolic disease, and diseases of aging.
Linnaeus is testing LNS8801, an oral GPER agonist, after a phase 1/2 study in more than 100 patients showed an exceptional safety and tolerability profile alongside signals in cancer survival and cardiometabolic measures. Its funding matters because a contract of up to $22 million from ARPA-H and $8.3 million in NCI support are financing the bet that one estrogen-signaling pathway can address cancer and healthspan, while selection for the NIA Interventions Testing Program adds independent lifespan testing.
Checked against 13 sources today
None named.
Also named as backers in company research: Kairos Ventures, Penn Medicine Co-Investment Fund at the University of Pennsylvania, GenHenn Capital, Advanced Research Projects Agency for Health (ARPA-H), National Cancer Institute, UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI)